Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...
NYSE: ABT
Abbott to Acquire Insulin Management Firm Bigfoot Biomedical
Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...
Abbott Partners with Sinopharm for Expanded Medical Solutions in China
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...
Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates
US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...
Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance
With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...